ClinicalTrials.gg
RecruitingNCT06807749PERSEVEREXUpdated Sep 3, 2026

Adjuvant Treatment in Premenopausal Breast Cancer

An observational study in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 2 sites in Italy. Open to female participants aged Up to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
800
Ages
Up to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 19 open to participants now, 23 under way, none of them phase 3. Breast Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
6th of 24
800 · median 288
Started
2025
with 5 others
Observational
24 of 32
16 open now
Primary completion
2027-09
later than 17 of 22 live
Registered
23rd of 32
by date

Among the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 6th largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2025, is one of 24 observational ones, reaches primary completion later than 17 of the 22 other live ones, and was the 23rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: Up to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.

Read the detailed description

Premenopausal patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 with any Recurrence Score (RS) and pathological nodal status pN0/pN1 will be included in the study. The study will collect clinical-pathological, genomic characteristics, adjuvant treatments (chemotherapy, endocrine therapy with/without OFS), and survival outcome (iDFS).

03

Conditions studied

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Browse trials for

Keywords

  • Premenopausal early breast cancer
  • Oncotype Dx
04

Who can participate

Ages eligible
Up to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with premenopausal early breast cancer HR+ HER2 negative diagnosis with any Recurrence Score (RS) and pathological nodal status pN0/pN1 and who underwent the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, premenopausal and ≥18 years age patients.
  2. Agree to participate in study and signing or declaration in lieu of informed consent form, if applicable
  3. Histological diagnosis of early breast cancer hormone positive (ER and/or PgR), -negative.
  4. Pathological nodal stage of pN0 or pN1 (1-3 nodes) and pathological tumor stage of pT1 to pT3.
  5. Surgery for primary breast cancer and axillary staging by sentinel node or axillary lymph node dissection (ALND).
  6. Availability of 21-multigene assay Oncotype DX recurrence score results performed according to physician choice from 1st January 2013 to 31st December 2022
  7. Availability of clinical and pathological information.
  8. Availability of information about treatment received.
  9. Availability of patient' outcome information (relapse, site of relapse, survival).

Exclusion criteria

Exclusion Criteria:

  1. Evidence of distant
  2. Inflammatory breast cancer
  3. treatment
  4. No surgery for primary breast cancer and axillary staging
  5. Patients not tested with 21-multigene assay Oncotype DX
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
800 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • node negative (pN0)

    Patients with node negative (pN0) diagnosis and availability of Recurrence Score at Oncotype Dx test

  • node positive (pN1)

    Patients with node positive (pN1) diagnosis and availability of Recurrence Score at Oncotype Dx test

06

What researchers measure

Primary outcomes

  1. Invasive Disease-Free Survival (iDFS) at 5 years

    The primary endpoint of the study will be the invasive Disease-Free Survival (iDFS) at 5 years among pN0 and pN1 premenopausal breast cancer patients in subgroups formed according to their genomic risk according to 21- multigene assay Oncotype DX.

    Time frame: up to 30 months

Secondary outcomes

  1. To describe the effect of the different adjuvant treatments according to clinical and genomic risk

    Descriptive statistics, statistical measure of association, and logistic binomial regression modeling of the association measures between the iDFS at 5 years and explicative variables including adjuvant treatment received (chemo/endocrine therapy; endocrine therapy with or without OSF), pathological tumor status, and genomic risk score according to 21-multigene assay Oncotype DX.

    Time frame: up to 30 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 21 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Feb 4, 2025
StartActual
Dec 24, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06807749
Collaborators
Clinical Research Technology S.r.l.
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Dec 24, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Clinical Research Technology
Contact
perseverex@cr-technology.com
0039 089 301545
Antonella Palazzo
principal investigator · Fondazione Policlinico Gemelli, IRCCS
Alessandra Fabi
study chair · Fondazione Policlinico Gemelli, IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion